最近我們發現4-anilinofuroquinoline衍生物如1-[4-(furo[2,3-b]quino line-4-ylamino)-phenyl]ethanone (CIL-102) (GI50 = 0.025 M), 1-[4-(3-chloro-7-methoxyfuro[2,3-b]quinolin-4-ylamino)-phenyl]etha- none 以及(CYL-698v)ethyl-4-(3-chloro-7-methoxyfuro[2,3-b]quinolin- 4-ylamino) benzoate (LHC-2608)具有抗癌的活性,這些化合物可以使細胞週期停滯在G2/M期,它們的抗癌機制是影響微小管的聚合作用而使有絲分裂失敗,造成細胞凋亡。根據structure-activity relationships的結果,為了增進這些化合物的抗癌活性,我們合成出一系列在furo[2,3-b]quinoline的4-C位置上具有anilines取代的衍生物,在本篇論文中所合成出的新衍生物,並沒有發現比CIL-102活性表現更優良的衍生物。
Recently, we have found certain 4-anilinofuroquinoline derivatives such as 1-[4-(furo[2,3-b]quinolin-4-ylamino)-phenyl]ethanone (CIL-102) (GI50 = 0.025 M) and 1-[4-(3-chloro-7-methoxyfuro[2,3-b]quinolin-4-ylamino) -phenyl]ethanone (CYL-698v) and ethyl-4-(3-chloro-7-methoxyfuro [2,3-b]quinolin-4-ylamino)benzoate (LHC-2608) to possess potent anticancer activities. These compounds arrest the cell cycle in G2/M phase. Further pharmacological evaluation revealed that these 4-anilino- furoquinolines interact with microtubule polymerization and causes mi- totic arrest followed by apoptosis. To optimize anticancer activities and to establish structure-activity relationships, we have synthesized a number of new entities with various substituents at 4-C position of 4-anilino moiety for antiproliferative evaluation. None of the newly syn- thesized 4-anilinofuroquinoline derivatives proved to be more potent than that of CIL-102 。